Home › Triple-Negative Breast Cancer › Maryland › Baltimore

Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa Baltimore, MD

Isang pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Baltimore. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Nagre-recruitPhase 3

MedStar Franklin Square Medical Center ( Site 0031), Baltimore
MedStar Good Samaritan Hospital ( Site 0079), Baltimore

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06841354

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Nagre-recruitPhase 3

Mercy Medical Center - Baltimore ( Site 0015), Baltimore

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06966700

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Nagre-recruitPhase 2

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT07340541

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Nagre-recruitPhase 1

United Theranostics, Glen Burnie · 9 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07020117

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Nagre-recruitPhase 2

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT03606967

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Nagre-recruitPhase 3

Sinai Hospital of Baltimore, Inc., Baltimore
St. Agnes Hospital, Baltimore
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
at 1 pa

Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT05633654

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Nagre-recruitPhase 2

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Edad 18 pataas · Kababaihan · Na-update Set 3, 2026 · NCT06245889

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Nagre-recruitPhase 2/3

Local Institution - 1035, Baltimore

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06926868

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

Nagre-recruitPhase 1

United Theranostics, Glen Burnie · 9 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 3, 2026 · NCT07311993

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Nagre-recruitPhase 1/2

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2025 · NCT05902988

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Nagre-recruitPhase 2

University of Maryland Medical Center (UMMC), Baltimore

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 19, 2025 · NCT06568692

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

Nagre-recruitPhase 1

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 28, 2022 · NCT05627960

Pag-aaral para sa Triple-Negative Breast Cancer sa ibang lungsod

Iba pang pag-aaral sa Baltimore

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.